JP6386527B2 - カリウムイオンチャネル阻害剤としてのピロロピリダジン - Google Patents

カリウムイオンチャネル阻害剤としてのピロロピリダジン Download PDF

Info

Publication number
JP6386527B2
JP6386527B2 JP2016500921A JP2016500921A JP6386527B2 JP 6386527 B2 JP6386527 B2 JP 6386527B2 JP 2016500921 A JP2016500921 A JP 2016500921A JP 2016500921 A JP2016500921 A JP 2016500921A JP 6386527 B2 JP6386527 B2 JP 6386527B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
compound
compounds
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016500921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512504A5 (enExample
JP2016512504A (ja
Inventor
ヘザー・フィンレイ
アショク・クマール・アディセチャン
プラシャンタ・グナガ
ジョン・ロイド
ポトゥカヌリ・スリニバス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016512504A publication Critical patent/JP2016512504A/ja
Publication of JP2016512504A5 publication Critical patent/JP2016512504A5/ja
Application granted granted Critical
Publication of JP6386527B2 publication Critical patent/JP6386527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016500921A 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロピリダジン Expired - Fee Related JP6386527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775742P 2013-03-11 2013-03-11
US61/775,742 2013-03-11
PCT/US2014/022238 WO2014143607A1 (en) 2013-03-11 2014-03-10 Pyrrolopyridazines as potassium ion channel inhibitors

Publications (3)

Publication Number Publication Date
JP2016512504A JP2016512504A (ja) 2016-04-28
JP2016512504A5 JP2016512504A5 (enExample) 2017-04-13
JP6386527B2 true JP6386527B2 (ja) 2018-09-05

Family

ID=50382739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500921A Expired - Fee Related JP6386527B2 (ja) 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロピリダジン

Country Status (6)

Country Link
US (1) US9458164B2 (enExample)
EP (1) EP2970295B1 (enExample)
JP (1) JP6386527B2 (enExample)
CN (1) CN105008366B (enExample)
ES (1) ES2616026T3 (enExample)
WO (1) WO2014143607A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143606A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008347A (zh) 2013-03-11 2015-10-28 百时美施贵宝公司 作为钾离子通道抑制剂的异喹啉类化合物
BR112020015444A2 (pt) * 2018-01-30 2020-12-08 Buckman Laboratories International, Inc Método para controlar o crescimento de pelo menos um microrganismo em um produto, método para controlar o crescimento de pelo menos um microrganismo contaminante em um estoque de abastecimento contendo carboidrato fermentável, método para produzir etanol por fermentação com crescimento controlado de microrganismos contaminantes e solução aquosa
EP4651951A1 (en) * 2023-01-19 2025-11-26 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2025008227A1 (en) 2023-07-05 2025-01-09 Basf Se Substituted pyridyl/pyrazinyl dihydropyrrolotriazine compounds for combatting phytopath-ogenic fungi
WO2025008226A1 (en) 2023-07-05 2025-01-09 Basf Se Substituted quinolyl/quinoxalyl dihydropyrrolotriazine compounds for combatting phyto-pathogenic fungi
WO2025077671A1 (zh) * 2023-10-09 2025-04-17 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
CA2373990C (en) * 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
HUP0303897A2 (hu) * 2000-11-17 2004-03-01 Bristol-Myers Squibb Company Eljárások p38 kinázzal összafüggő esetek kezelésére, kináz inhibitorokként alkalmazható pirrolotriazin vegyületek és ezeket tartalmazó gyógyszerkészítmények
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
BRPI0410097A (pt) * 2003-05-07 2006-05-16 Pharmacia & Upjohn Co Llc compostos de pirrol[1,2-b]piridazina
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2134716A1 (en) * 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2010001824A (es) * 2007-08-17 2010-04-21 Icagen Inc Heterociclos como moduladores de canal de potasio.
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
AR077428A1 (es) 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
HRP20161669T1 (hr) 2009-09-03 2017-02-24 Bristol-Myers Squibb Company Kinolini kao inhbitori kalijevih ionskih kanala
EP2623505B1 (en) 2010-09-29 2015-07-29 Kissei Pharmaceutical Co., Ltd. (aza)indolizine derivatives as xanthine oxidase inhibitors
WO2012125893A1 (en) * 2011-03-17 2012-09-20 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
EP2685982B1 (en) * 2011-03-17 2017-07-05 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
US8921368B2 (en) * 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
MY169219A (en) * 2012-06-11 2019-03-19 Bristol Myers Squibb Co Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 ? sulfonamide
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143606A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008347A (zh) 2013-03-11 2015-10-28 百时美施贵宝公司 作为钾离子通道抑制剂的异喹啉类化合物
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
CN105008366A (zh) 2015-10-28
US9458164B2 (en) 2016-10-04
CN105008366B (zh) 2017-11-14
JP2016512504A (ja) 2016-04-28
WO2014143607A1 (en) 2014-09-18
ES2616026T3 (es) 2017-06-09
EP2970295B1 (en) 2016-12-28
US20160016961A1 (en) 2016-01-21
EP2970295A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP6427551B2 (ja) カリウムイオンチャネル阻害剤としてのピロロトリアジン
KR101698631B1 (ko) 칼륨 이온 채널 억제제로서의 퀴나졸린
JP6386527B2 (ja) カリウムイオンチャネル阻害剤としてのピロロピリダジン
JP6427164B2 (ja) カリウムイオンチャネル阻害剤としてのフタラジン
JP2009507849A (ja) 非環状ＩＫｕｒインヒビター
JP2016516691A (ja) カリウムイオンチャネル阻害剤としてのイソキノリン
JP6395798B2 (ja) カリウムイオンチャネル阻害剤としてのピロロトリアジン
ES2349753T3 (es) Derivados de piperidina como profármacos de inhibidores de los canales de potasio.
TW202434590A (zh) 稠合雙環化合物
JP2024511617A (ja) 新規なインドールアミン－２，３－ジオキシゲナーゼ阻害剤、その製造方法、およびそれを含む医薬組成物
TW201514162A (zh) 作爲鉀離子通道抑制劑之呔

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180809

R150 Certificate of patent or registration of utility model

Ref document number: 6386527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees